# Heart Failure FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/heart-failure

> 10 upcoming FDA catalysts in heart Failure: BMS-986435 (BMY) on Dec 2026 to Mar 2027 (topline data readout); BMS-986435 (BMY) on December 2026 (primary completion); CDR132L (NVO) on May to Aug 2027 (topline data readout); CDR132L (NVO) on May 2027 (primary completion); and 6 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| June 2, 2025 | [REGN5381 primary completion](https://sec-api.dev/pdufa/regn5381) | REGN | Heart Failure | completed | "NCT05353166 (REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge Pressure): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-02 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals; Results First Posted 2026-09-29." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05353166)) |
| Q3 2025 | [Edg-15400 25 mg trial start](https://sec-api.dev/pdufa/edg-15400) | EWTX | heart failure | scheduled | "During the third quarter of 2025, the Company expects to begin dosing in a first-in-human Phase 1 trial of EDG-15400, a novel drug candidate intended for the treatment of heart failure." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710072/000110465925074987/tm2522645d1_ex99-1.htm)) |
| September 17, 2025 | [REGN5381 primary completion](https://sec-api.dev/pdufa/regn5381) | REGN | Heart Failure | withdrawn | "NCT06237309 (REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-09-17 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06237309)) |
| September 3, 2026 | [Ziltivekimab primary completion](https://sec-api.dev/pdufa/ziltivekimab) | NVO | Heart Failure | withdrawn | "NCT05636176 (A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2026-09-03 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05636176)) |
| September 29, 2026 | [REGN5381 topline data readout](https://sec-api.dev/pdufa/regn5381) | REGN | Heart Failure | completed | "NCT05353166 (REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge Pressure): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-02 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals; Results First Posted 2026-09-29." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05353166?tab=results)) |
| Dec 2026 to Mar 2027 | [BMS-986435 topline data readout](https://sec-api.dev/pdufa/bms-986435) | BMY | Heart Failure | scheduled | "NCT06122779 (Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-14 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06122779)) |
| December 2026 | [BMS-986435 primary completion](https://sec-api.dev/pdufa/bms-986435) | BMY | Heart Failure | scheduled | "NCT06122779 (Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-14 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06122779)) |
| May to Aug 2027 | [CDR132L topline data readout](https://sec-api.dev/pdufa/cdr132l) | NVO | Heart Failure | scheduled | "NCT06979375 (A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-05-16 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06979375)) |
| May 2027 | [CDR132L primary completion](https://sec-api.dev/pdufa/cdr132l) | NVO | Heart Failure | scheduled | "NCT06979375 (A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-05-16 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06979375)) |
| Nov 2027 to Feb 2028 | [CDR132L topline data readout](https://sec-api.dev/pdufa/cdr132l) | NVO | Heart Failure | scheduled | "NCT06979362 (A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-16 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06979362)) |
| November 2027 | [CDR132L primary completion](https://sec-api.dev/pdufa/cdr132l) | NVO | Heart Failure | scheduled | "NCT06979362 (A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-16 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06979362)) |
| May to Aug 2028 | [Low dose pf-07328948 topline data readout](https://sec-api.dev/pdufa/low-dose-pf-07328948) | PFE | Heart Failure | scheduled | "NCT06991257 (A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-05-08 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06991257)) |
| May 2028 | [Low dose pf-07328948 primary completion](https://sec-api.dev/pdufa/low-dose-pf-07328948) | PFE | Heart Failure | scheduled | "NCT06991257 (A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-05-08 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06991257)) |
| Dec 2029 to Mar 2030 | [Baxdrostat and dapagliflozin topline data readout](https://sec-api.dev/pdufa/baxdrostat-and-dapagliflozin) | AZN | Heart Failure | scheduled | "NCT06677060 (Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-17 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06677060)) |
| December 2029 | [Baxdrostat and dapagliflozin primary completion](https://sec-api.dev/pdufa/baxdrostat-and-dapagliflozin) | AZN | Heart Failure | scheduled | "NCT06677060 (Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-17 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06677060)) |

## Drugs

- [REGN5381](https://sec-api.dev/pdufa/regn5381) (REGN)
- [Edg-15400 25 mg](https://sec-api.dev/pdufa/edg-15400) (EWTX)
- [Ziltivekimab](https://sec-api.dev/pdufa/ziltivekimab) (NVO)
- [BMS-986435](https://sec-api.dev/pdufa/bms-986435) (BMY)
- [CDR132L](https://sec-api.dev/pdufa/cdr132l) (NVO)
- [Low dose pf-07328948](https://sec-api.dev/pdufa/low-dose-pf-07328948) (PFE)
- [Baxdrostat and dapagliflozin](https://sec-api.dev/pdufa/baxdrostat-and-dapagliflozin) (AZN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/heart-failure.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Heart Failure FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/heart-failure

```bibtex
@misc{secapidev_indications_heart_failure_20261116,
  title        = {Heart Failure FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/heart-failure}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_heart_failure_20261116","title":"Heart Failure FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/heart-failure","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
